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Summary
 
Antigen presentation by major histocompatibility complex (MHC) class I molecules requires
peptide supply by the transporters associated with antigen processing (TAPs), which select sub-
strates in a species- and, in the rat, allele-specific manner. Conflicts between TAPs and MHC
preferences for COOH-terminal peptide residues in rodent cells strongly reduce the efficiency
of MHC class I antigen presentation. Although human TAP is relatively permissive, some pep-
tide ligands for human histocompatibility leukocyte antigen class I molecules are known to
possess very low TAP affinities; the significance of these in vitro findings for cellular antigen
presentation is not known. We studied two naturally immunodominant viral epitopes presented
by HLA-A2 that display very low affinities for human TAP. Low TAP affinities preclude mini-
mal epitope access to the endoplasmic reticulum (ER) and assembly with HLA-A2 in vitro, as
well as presentation by minigene-expressing cells to cytotoxic T lymphocytes. However,
 
 
 
NH
 
2
 
-
terminally but not COOH-terminally extended epitope variants with higher TAP affinities
 
assemble in vitro and are presented to cytotoxic T lymphocytes with high efficiency. Thus,
human TAP can influence epitope selection and restrict access to the ER to epitope precursors.
Analysis of TAP affinities of a panel of viral epitopes suggests that TAP selection of precursors
may be a common phenomenon for HLA-A2–presented epitopes. We also analyzed HLA-
A2–eluted peptides from minigene-expressing cells and show that an NH
 
2
 
-terminally extended
variant with low A2 binding affinity undergoes ER processing, whereas another with high af-
finity is presented unmodified. Therefore, the previously reported aminopeptidase activity in
the ER can also act on TAP-translocated peptides.
Key words: antigen presentation • ABC transporters • immunodominant epitopes • 
HLA class I • aminopeptidases
 
H
 
uman histocompatibility leukocyte antigen class I (HCI)
 
1
 
molecules present short peptides with a length of 8–10
residues to CTLs. Most of these peptides are derived from
degradation of cellular proteins by the cytosolic proteasome
complex and translocated into the endoplasmic reticulum
(ER) by the heterodimeric complex of the transporters as-
sociated with antigen processing (TAPs) (for review see
references 1–3). This pump is inserted into the membranes
of ER and cis-Golgi compartments and delivers peptides to
empty HCI/
 
b
 
2-microglobulin (
 
b
 
2
 
m) dimers that associate
with TAP with the help of the 48-kD protein tapasin, whose
function remains unclear (4).
An important unresolved question concerns the contribu-
tion of the different steps in antigen processing to selection of
immunodominant epitopes. Studies of the relationship be-
tween peptide affinity for MHC class I molecules and effi-
ciency of presentation have demonstrated that high MHC
binding affinity generally is a necessary but insufficient pre-
requisite for immunogenicity; this suggests additional roles
for antigen processing and/or the T cell repertoire (5, 6).
Selective TAP transport is one of the principal candidate
 
1
 
Abbreviations used in this paper: 
 
b
 
2
 
m, 
 
b
 
2-microglobulin; BFA, brefeldin A;
Ct, COOH-terminal; ER, endoplasmic reticulum; HBV, hepatitis B virus;
HCI, HLA class I; HCV, hepatitis C virus; MOI, multiplicity of infection;
Nt, NH
 
2
 
-terminal; TAPs, transporters associated with antigen processing. 
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mechanisms for epitope selection during processing. The
principles of peptide selection by rodent and human TAP
transporters have been studied in detail using two in vitro
assays (7, 8). TAP transporters display species- and (in the rat)
allele-specific substrate selectivities, the level of which is
highest for murine TAP and rat TAP1–TAP2
 
b
 
 complexes
and significantly lower for human
 
 
 
TAP; TAP selects sub-
strates according to the COOH-terminal (Ct) residue fol-
lowed by the three NH
 
2
 
-terminal (Nt) residues (7–9).
The significant potential impact of TAP selectivity on
antigen presentation was first demonstrated by Powis et al.,
who studied rat cells expressing TAP transporters and MHC
class I molecules with incompatible preferences for Ct pep-
tide residues (10). This conflict impairs efficiency of antigen
presentation so significantly that incompatible TAP/MHC
combinations do not occur naturally in rat strains that have
not been selected for recombined MHC regions (11). Pep-
tide selection by murine TAP can also affect antigen pre-
sentation, as shown recently by Yellen-Shaw et al. (12); in
this case, TAP selection was unfavorable for peptides with
Ct residues that are not preferred by murine MHC class I
molecules, confirming the absence of conflicting TAP and
MHC preferences in naturally selected rodent strains. In-
terestingly, detection of peptide selection by TAP required
limitation of minigene expression, demonstrating that low
TAP affinities could be overcome by abundant peptide lev-
els in the cytosol (12).
Human TAP transporters are more permissive than mu-
rine or rat TAP-B transporters and accept peptides with all
Ct residues generally found in HCI-binding peptides, albeit
with different efficiencies (9, 13). Nevertheless, variations
of the three Nt and the Ct peptide residues that together
determine peptide affinity for TAP can cause dramatic dif-
ferences in peptide affinity for TAP (8, 9). As human TAP
preferences are much more compatible with those of some
HCI alleles such as HLA-B27 than those of others such as
HLA-A2, potential ligands for some HCI molecules fre-
quently possess low TAP affinities (14). The biological con-
sequences of this phenomenon, and more generally those
of human TAP selectivity, have so far not been investi-
gated. Several scenarios may account for efficient HCI-medi-
ated presentation of peptides with very low TAP affinities
and for efficient antigen presentation by HCI alleles that
prefer ligands with low TAP affinities. First, high cytosolic
concentrations of peptides with low TAP affinities may over-
come inefficient TAP transport, as indeed has been demon-
strated in the murine experimental system cited above (12).
Second, HCI alleles with poorly TAP-adapted peptide pref-
erences may present a smaller array of epitopes due to inef-
ficient TAP-mediated ER access for numerous potential
ligands. Finally, these alleles may frequently present pep-
tides that enter the ER as precursors with higher TAP af-
finities and are then processed to the final epitope within
the ER. We and others have previously found circumstan-
tial in vitro evidence consistent with the latter hypothesis:
in TAP binding (8) as well as transport (15) assays, extended
precursors of some epitopes with low TAP affinities were
found to possess higher TAP affinities. However, neither lack
of epitope presentation due to low affinity for human TAP
nor reconstitution of epitope presentation due to ER entry
of precursors with higher TAP affinities has so far been
demonstrated in cellular assays. Given the exquisite sensitivity
of epitope recognition by CTLs and the phenomenon of a
relatively low threshold for efficient antigen processing
(16), it can be argued that even extremely inefficient TAP
transport, as observed in in vitro assays, may be sufficient for
epitope presentation (17).
The hypothesis of epitope precursor transport as a rescue
pathway for poor TAP/MHC coordination or as a way of
increasing the variety of HCI-presented peptides implies an
efficient mechanism for peptide adaptation to MHC class I
binding requirements in the ER. Although ER peptidases
involved in maturation of antigenic peptides have not been
identified, available evidence indicates that antigenic pep-
tides can be modified by an aminopeptidase activity, whereas
COOH terminals cannot be modified in the ER (10, 18, 19).
This conclusion is based on experiments in which expres-
sion of signal peptide–coupled protein fragments or epitope
precursors in TAP-deficient APCs resulted in efficient
 
 
 
release
and presentation of epitopes (19–21). Epitopes can also be
liberated by an aminopeptidase activity from the COOH
terminus of the type 2 transmembrane protein Jaw 1 (22). Nt
trimming of epitopes in the ER is consistent with the ca-
pacity of TAP to transport long peptides (8, 23) and with
observations suggesting that the proteasome very often gen-
erates the COOH terminals and frequently, but not always,
the NH
 
2
 
 terminals of MHC class I–presented epitopes (24).
Even though there is clear evidence for an aminopepti-
dase activity in the ER, some observations suggest that its
efficiency may be limited or that it may not act on all pep-
tide–MHC complexes. A subset of cell surface HLA-B27
molecules present long peptides unlikely to have been sub-
jected to a peptide maturation mechanism (25). Moreover,
a recent analysis of peptide assembly with HLA-B27 in tapa-
sin-deficient cells suggests that tapasin may be important for
optimization of HCI-presented peptides (26). Because evi-
dence for Nt epitope maturation in the ER was obtained
using signal peptide–coupled epitopes and because it is not
known whether such epitopes assemble with HCI molecules
in tapasin-associated loading complexes, processing of sig-
nal peptide–coupled epitopes may not fully reflect that of
TAP-transported peptides. The finding that most signal
sequence–derived peptides eluted from HLA-A2 in TAP-
deficient cells are longer than the standard 8–10 residues (27)
is compatible with the hypothesis that HCI ligands from this
alternative source may not be subjected to the same editing
mechanisms as TAP-supplied peptides. Thus, although most
authors agree that available evidence renders Nt ER pro-
cessing of TAP-transported peptides likely (1, 3, 18), it is
important to provide direct evidence for this suggestion; no
example of ER processing of a TAP-transported peptide
has been provided as yet.
We have studied biological effects of the selectivity of
human TAP and potential peptide processing in the ER in
the models of two naturally immunodominant viral epitopes
presented by HLA-A2. We find that the selectivity of human 
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TAP complexes effectively precludes presentation of these
short epitopes expressed as minigenes in the cytosol and fa-
vors ER access of longer precursor peptides. As revealed by
analysis of HLA-A2–eluted peptides, TAP-transported pre-
cursors with low HCI binding affinity can undergo rapid and
complete processing in the ER.
 
Materials and Methods
 
Peptides, Antibodies, and Cell Lines
 
The panel of HLA-A2 binding peptides derived from hepatitis B
virus (HBV) and hepatitis C virus (HCV) sequences has been de-
scribed previously (28, 29). Peptide HBV pol 575-83 (FLLSLGIHL)
and its variant 573-83, HBV core 18-27 (FLPSDFFPSV) and its
variants 17-27 and 18-28, reporter peptides HLTV-I tax 11-19
(LLFGYPVYV), HIV gag 77-85 (SLYNTVATL), R-9-L (RRY-
NASTEL), R-10-T (RYWANATRST), S-9-R (SRYWAIRTR),
S-11-R (SRYWNATIRTR), and F-10-V (FLPSDYFPSV) were
all obtained 
 
.
 
96% pure from Genosys
 
.
 
 HBV epitope variants pol
575-87, 573-87, and core 17-28 were synthesized with 
 
.
 
95% purity
by the peptide synthesis facility of the Scripps Research Institute.
Hybridomas BB7.2 with specificity for HLA-A2 and IVD12
recognizing HLA-DQ were purchased from American Type Cul-
ture Collection (ATCC). HLA-A2–expressing B cells used in
this study were provided by the Centre pour l’Etude du Poly-
morphisme Humain (Paris, France) or A. Toubert (Hôpital St.
Louis, Paris, France) and included homozygous lines Jesthom and
JY and mutant line T2. RMA-S cells transfected with “HHD”
HLA-A2/K
 
d
 
 molecules were grown with 1 mg/ml gentamycin
and 10
 
2
 
5
 
 M 
 
b
 
-ME as described (30).
 
TAP Peptide Binding Assay
 
Peptide binding to human TAP complexes was measured as
described (8) using reporter peptide R-9-L at 300 nM.
 
Translocation Assays
 
Human B cell lines were washed once in translocation buffer
(130 mM KCl, 10 mM NaCl, 1 mM CaCl
 
2
 
, 2 mM EGTA, 2 mM
MgCl
 
2
 
, 2 mM dithiothreitol, and 5 mM Hepes, pH 7.3) and per-
meabilized for 5 min at 37
 
8
 
C with 1 IU/ml streptolysine O be-
fore addition of reporter and competitor peptides and ATP (2 mM).
After incubation for 20 min at 37
 
8
 
C, cells were lysed by addition
of 800 
 
m
 
l cold lysis buffer (500 mM NaCl, 50 mM Tris, 5 mM
MgCl
 
2
 
, and 1% Triton X-100, pH 7.4) with a cocktail of pro-
tease inhibitors. After a 30-min incubation on ice, lysates were
clarified by centrifugation at 15,000 
 
g
 
 for 10 min at 4
 
8
 
C, and su-
pernatants were recovered for affinity purification of HLA-A2
molecules or glycosylated peptides.
 
Transport of Peptides with Glycosylation Acceptor Sequence.
 
These
assays were carried out as described by Neefjes et al. (31) using
1.5 
 
3
 
 10
 
6
 
 cells in a volume of 100 
 
m
 
l and 160 nM iodinated re-
porter peptide. Reporter peptides R-10-T or S-11-R were used.
Glycosylated reporter peptides were recovered by 2-h incuba-
tions of cleared supernatants with 100 
 
m
 
l Con A–Sepharose beads
at 4
 
8
 
C. Beads were washed four times with assay buffer before
counting of bound radioactivity. 100% accumulation corresponded
to 
 
z
 
15,000 cpm.
 
Transport of Peptides Binding to HLA-A2.
 
Based on published
methods (32), 5 
 
3
 
 10
 
6 
 
B cells/sample in 300 
 
m
 
l buffer with 130
nM reporter peptide were used. Reporter peptide S-9-L was used
in TAP-proficient cells, and L-9-V was used in TAP-deficient cells.
For TAP-independent peptide translocation, no ATP was added.
 
After the incubation period, cells were pelleted to remove excess
reporter peptide, washed in 800 
 
m
 
l buffer, and lysed. HLA-A2
molecules were then immunoprecipitated for 20 min (4
 
8
 
C) with
10 
 
m
 
g mAb BB7.2 preadsorbed on 15 
 
m
 
l protein A–Sepharose
beads. 100% accumulation corresponded to 
 
z
 
15,000 cpm.
Peptides were iodinated by the chloramin T method using 12
nmol peptide, 0.5 mCi 
 
125
 
I, and 0.5 mg/ml chloramin T (Merck)
for peptides F-10-V, S-9-L, and L-9-V. For R-9-L, R-10-T, and
S-11-R peptides, 1 mCi 
 
125
 
I and 2 mg/ml chloramin T were used.
Free iodine was removed on Sephadex G10 columns. For peptides
S-9-L and L-9-V, 30% dimethylformamide was added to PBS la-
beling buffer. Specific activity of iodinated peptides was between
2.5 and 6 
 
3
 
 10
 
4
 
 cpm/pmol.
In competition experiments, cpm corresponding to 50% inhi-
bition of specific peptide binding to TAP or of accumulation of
glycosylated or A2-bound peptide in the ER was determined
graphically as described (8). Nonspecific binding, i.e., binding of
iodinated peptide to control TAP1 microsomes, or peptide re-
covered upon incubation of Con A or BB7.2 beads with lysates
of nonpermeabilized cells was 
 
,
 
2% of specific binding in the ab-
sence of competitor unless indicated otherwise.
 
Purification of HLA-A2 Molecules
 
Purified mAb BB7.2 (or glycine at 10 mM) was coupled to cy-
anobromide-activated Sepharose 4B beads at a ratio of 7.5 mg
mAb/ml resin. 3 
 
3
 
 10
 
9
 
 Jesthom cells were lysed for 1 h at 4
 
8
 
C in
60 ml lysis buffer containing 50 mM Tris, pH 7.4, 150 mM
NaCl, 1% Triton X-100, and a cocktail of protease inhibitors.
Clarified lysate was precleared by incubation with 900 
 
m
 
l glycine–
Sepharose beads for 3 h and incubated overnight at 4
 
8
 
C with 175
 
m
 
l BB7.2–Sepharose (corresponding to 1.3 mg mAb). Beads were
washed with a series of cold lysis buffers (5 ml each, with 0.1–0.5%
Triton X-100) with pH 7.4, pH 8, and pH 9, and, finally, once
with 1.8 ml of 250 mM NaCl, 0.1% Triton X-100, and 10 mM
Tris, pH 9. HLA-A2 molecules were eluted twice with 500 
 
m
 
l of
50 mM triethanolamine, 150 mM NaCl, and 0.1% SDS, pH 11.5,
and immediately neutralized by addition of 150 
 
m
 
l of 1 M Tris,
pH 6.8. Eluates were dialyzed against PBS buffer containing 0.05%
Triton X-100. HLA-A2 concentration in eluates was quantified
in Coomassie-stained SDS-PAGE gels.
 
HLA-A2 Peptide Binding Assay
 
To measure peptide binding to HLA-A2, we developed an
assay derived by modification of published procedures (33, 34).
350 ng of HLA-A2 was incubated in a total volume of 20 
 
m
 
l PBS
with 0.05% Triton X-100 and protease inhibitors with 0.5 
 
m
 
g
human 
 
b
 
2
 
m, 3 
 
m
 
l iodinated reporter peptide F-10-V, and com-
petitor peptides. After incubation for 2 d at 25
 
8
 
C, HLA-A2 mol-
ecules were separated from free peptide by size exclusion chro-
matography on Biogel P-30™ spun columns (Bio-Rad Labs.)
equilibrated in PBS buffer containing 0.5% Triton X-100. Cpm
eluting in the void volume corresponded to HLA-A2–bound pep-
tide and was corrected by subtracting cpm leaking through columns
loaded with peptide only. In the absence of competitor peptides,
 
z
 
40,000 cpm reporter peptide bound to HLA-A2 molecules.
 
CTLs
 
Three approaches were used to generate CTL lines specific for
HBV epitopes: human lines primed in vitro, lines from HBV pa-
tients, and lines from HLA-A2–transgenic mice. A total of nine
independent CTL lines was used for experiments shown and/or
referred to in this paper: for HBV pol 575-83, two lines from in
vitro immunization, and one from a patient; for HBV core 18-27, 
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one line from in vitro immunization, two from patients, one from
conventional and two from single chain–transgenic mice. As most
CTL lines lost specificity upon freezing, it was not always possi-
ble to use the same line for subsequent experiments concerning
one epitope; experiments were therefore generally repeated with
different CTL lines.
 
In Vitro Induction of Peptide-specific CTL Lines.
 
CTL lines were
generated by coculture of PBMCs from healthy HLA-A2
 
1
 
 donors
with cells from a second donor with a high proliferative response
to tetanus toxoid in a transwell system (Costar Corp.) using a
modification of published procedures (35). In brief, PBMCs were
seeded into 24-well plates at 4 
 
3
 
 10
 
6
 
 cells/well in RPMI 1640
with 10% pooled human AB serum in the presence of 10 
 
m
 
g/ml
HBV peptide, 1 
 
m
 
g/ml tetanus toxoid, and 10
 
6
 
 PBMCs of the
second donor in the inner well. Unlike in the published protocol,
recombinant human IL-7 was added on day 3 at 50 U/ml. Cul-
tures were restimulated weekly with autologous irradiated PBMCs
prepulsed with peptide. Starting on day 7, cultures were main-
tained in 10 U/ml human IL-2 and 50 U/ml IL-7. Once CTL lines
exhibited target cell lysis 
 
.
 
30%, IL-2 concentration was increased
to 50 U/ml. Almost 90% of peptide-specific CTL lines obtained by
in vitro immunization did not recognize naturally processed pep-
tide, a phenomenon already documented in previous reports (36).
 
Generation of HBV-specific CTL Lines from Patients with Acute HBV
Infections.
 
CTL lines from HBV-infected patients were generated
exactly as described previously (37).
 
DNA Immunization of HLA-A2.1–transgenic Mice.
 
D
 
b
 
 and mouse
 
b
 
2
 
m double-knockout mice expressing an HLA-A2.1/human 
 
b
 
2
 
m
(HHD) single chain molecule (30) and conventional HLA-A2–
transgenic mice (38) were injected in the regenerating anterior
tibialis muscle of each leg (5 d after injection of cardiotoxin in the
same sites) with 50 
 
m
 
g cesium chloride–purified plasmids, corre-
sponding to HBV sequences encoding the pol protein (nucleo-
tides 2290–1874) or the core protein (1887–2800) cloned into
pcDNA3™ (Invitrogen Corp.) with a CMV promoter. 3 wk later,
spleens were removed and spleen cells were restimulated with an
equal number of irradiated LPS blasts prepulsed with 1 
 
m
 
M pep-
tide; peptide stimulation was repeated weekly until specific cyto-
toxic activity was detected. Blasts were generated by culture of
spleen cells from HHD mice for 3 d at 10
 
6
 
 cells/ml in RPMI
supplemented with 25 
 
m
 
g/ml yeast LPS and 7 
 
m
 
g/ml dextran
sulfate.
 
Vaccinia Viruses
 
Selected peptides were expressed as minigenes under the con-
trol of the p7.5 promoter in vector pSC11ss modified by inser-
tion of a sequence containing BglII, KpnI, NsiI, and NotI sites
between the SalI and StuI sites. Complementary oligonucleotides
comprising an ATG initiation codon and a stop codon with ap-
propriate cohesive ends were purchased from Genosys, annealed
by slow cooling from 70 to 30
 
8
 
C, and ligated overnight at 14
 
8
 
C
to modified pSC11ss. To express epitopes preceded by a signal
sequence, oligonucleotides corresponding to the signal peptide of
adenovirus E3/19K protein (20) were cloned into the KpnI/NotI
sites of modified pSC11ss, followed by insertion of minigenes
coding for epitopes HBV pol 575-83 or core 18-27 into the NotI/
StuI sites downstream. Oligonucleotides corresponding to HBV pol
575-83 and 573-83 were cloned into the SalI/StuI sites; for pep-
tides HBV core 18-27, 17-27, and 17-28, SalI/NsiI sites were used.
Insertion of correct minigene sequences was verified by sequenc-
ing. Recombinant viruses were generated by cotransfection of
CV-1 cells freshly infected by viral strain WR (ATCC) at a multi-
plicity of infection (MOI) of 0.1–1.0 with plasmids containing
 
minigenes together with 150 ng wild-type vaccinia DNA, fol-
lowed by selection of recombinant viral plaques in HuTK cells
and large-scale production of viruses in HeLa S3 cells according
to standard procedures. Recombinant vaccinia viruses coding for
the entire HBV polymerase and core proteins have been described
previously (37).
 
CTL Assay
 
Cytolytic activity was measured in 5-h 
 
51
 
Cr-release assays using
a standard protocol with 3,000 targets per well in RPMI 1640 sup-
plemented with 5% FCS. When sensitization by recombinant vac-
cinia viruses was tested, 1.5 
 
3
 
 10
 
6
 
 target cells were infected for 1.5 h
at an MOI of 10 in medium with 2.5% FCS. Cells were washed
once in 0.9% NaCl buffer, incubated for 3.5 h at 37
 
8
 
C in medium
with 10% FCS, and then labeled with 100 
 
m
 
Ci of Na
 
2
51
 
CrO
 
4
 
 for 1 h
at 37
 
8C. Cells were washed in 0.9% NaCl with 2% FCS, incubated
for 1 h at 378C, and washed again. To test sensitization by syn-
thetic or HLA-A2–eluted peptides, target cells were incubated for
1.5 h during or after cell labeling with peptides. In experiments with
brefeldin A (BFA), target cells were incubated for 2 h at 378C with
5 mg/ml BFA; BFA concentration was maintained at 5 mg/ml
throughout sensitization by peptide or virus by two-hourly replace-
ment of medium. BFA concentration during the 5-h killing assay
was 0.5 mg/ml (39). Percent specific lysis was calculated according
to the formula, (experimental cpm 2 spontaneous release)/([total
release/2] 2 spontaneous release); only experiments with ,20%
spontaneous release were considered.
Extraction and Analysis of Peptides Bound to
HLA-A2 Molecules
Large-Scale Infection of Cells and Purification of HLA-A2 Molecules.
HLA-A2–bound peptides were analyzed using a modification of
published methods (21): 1.6 (or 1.3 in the experiment shown in
Fig. 6, E and F) 3 109 JY cells were infected for 2 h at 108 cells/
ml and an MOI of 10 (5 in Fig. 6, E and F) with vaccinia virus.
After incubation for 6–8 h at 378C, cells were harvested, washed
once in cold PBS with 1 mM PMSF, and lysed as in the protocol
for HLA-A2 purification. Clarified detergent lysate was precleared
by incubation with 150 ml packed Sepharose beads coupled to mAb
IVD12 (corresponding to 750 mg mAb) for 3 h and then incubated
overnight at 48C with 90 ml (i.e., 675 mg) BB7.2–Sepharose beads.
IVD12 and BB7.2–Sepharose beads were washed with 10 bed
volumes of 50 mM Tris, 150 mM NaCl, pH 8.0, with 0.5%
NP-40 (Sigma Chemical Co.), then with 10 volumes of buffer
without NP-40, and finally with 10 volumes of 10 mM Tris, pH
8.0. Material bound to beads was eluted by two 5-min incuba-
tions in three volumes of 0.1% TFA (Sigma Chemical Co.); eluted
peptides were separated from higher molecular weight material
by centrifugation through Centricon 10 (Amicon, Inc.) devices
and finally dried by vacuum centrifugation.
HPLC Analysis and Fractionation.  Dried eluate was resuspended
in 100 ml 0.1% TFA and fractionated by reversed-phase HPLC
using a SMART system (Pharmacia). mRPC C2/C18™ 2.1/10
columns were run in 0.1% TFA (solvent A) and 80% acetonitrile
containing 0.081% TFA (solvent B). HPLC conditions were cali-
brated using synthetic peptides and chosen so as to allow maximal
resolution of minimal epitopes and precursors. The following gra-
dients were used: peptides HBV pol 575-83 and 573-83: 0–5 min,
linear increase from 0% B to 48% B; 45–57 min, linear increase
to 53% B; 57–65 min, linear increase to 90% B. Peptides HBV
core 18-27 and 17-27: 0–40 min, linear increase from 0 to 38.8%
B; 40–80 min, linear increase to 39.8% B; 80–90 min, linear in-
crease to 90% B; a slightly different gradient was used in the ex-1231 Lauvau et al.
periment in Fig. 6 E. Flow rate was maintained at 100 ml/min,
and fractions of 100 ml (peptides pol 575-83 and 573-83) or 250
ml (peptides core 18-27 and 17-27, HBV core protein) were col-
lected. Fractions were dried in a vacuum centrifuge and resus-
pended in 50 ml PBS with 5% DMSO. Fractionated peptide elutions
were tested using TAP-deficient T2 or RMA-S HHD cells prein-
cubated for 36 h at 278C to increase surface expression of HLA-A2
(30) before pulsing with 5 ml of each fraction; in the experiment
shown in Fig. 6 E, 20 ml of each fraction was used for pulsing.
Results
HLA-A2–presented Viral Epitopes Frequently Have Low TAP
Affinities. To establish a system in which the biological ef-
fect of human TAP selectivity and potential ER processing
of TAP-translocated peptides could be studied, we sought
to identify peptides with low transporter affinities that might
enter the ER exclusively in an extended form. Having pre-
viously observed that ligands for certain HCI molecules,
especially HLA-A2, frequently display low affinities for hu-
man TAP (8, 14), we tested a panel of peptides with high or
intermediate HLA-A2 binding affinity (6) (50% inhibiting
concentration [IC50] of 0.47–400 nM) derived from HBV and
HCV proteins for binding to human TAP complexes (40).
Among 34 tested peptides, 8 HBV peptides (Fig. 1) and 3
HCV peptides have been found to be antigenic in hepatitis
patients and can therefore be naturally processed and pre-
sented to CTLs (29, 37). Relative affinities measurable in
the TAP binding assay range from 0.1 to 3,000. 18/25 HBV
peptides (Fig. 1), and 5/8 HCV peptides (not shown) de-
rived from HBV proteins had low (IC50 .300) or unmeasur-
able TAP affinity. Thus, most peptides derived from HBV
and HCV that bind to HLA-A2 and in many cases induce ef-
ficient CTL responses in vivo had low TAP affinities, raising
the question of how these peptides obtain access to ER-resi-
dent HLA-A2 molecules for efficient presentation. Based on
the criteria of strong antigenicity in vivo and low TAP affin-
ity, we chose to study two HLA-A2–presented peptides with
unmeasurable TAP affinity, HBV pol 575-83 and core 18-27.
HLA-A2 Binding Affinity of HBV Epitopes and Extended
Variants. For each of the two HBV epitopes with very low
TAP affinity, we designed precursor peptides by extending
epitopes to the closest likely proteasome cleavage site (2, 24)
flanking their NH2 and/or COOH termini in the natural
protein sequence. Sequences of minimal and extended pep-
tides are shown in Fig. 2. Peptides extended by an Nt methio-
nine residue were also tested, as such peptides may result
from incomplete processing of minigene-expressed epitopes
by cytosolic methionine aminopeptidase. We then proceeded
to an in vitro evaluation of parameters that should affect
efficiency of peptide presentation: HLA-A2 binding affin-
ity, TAP binding and transport efficiency, and efficiency of
TAP-independent ER access.
To measure HLA-A2 binding affinity, we adopted a
published competition binding assay with immunoaffinity-
purified HLA-A2 molecules (33, 34). Measurable competi-
tor peptide affinities (IC50) range from 0.1 to 100. Simple ex-
tension of epitope pol 575-83 by naturally found residues at
either end surprisingly did not change HLA-A2 binding af-
finity (Fig. 2); however, Nt addition of methionine or ex-
tension at both ends decreased affinity. In contrast, all mod-
ifications of core 18-27 strongly reduced A2 affinity; this
result is in accordance with a previous study that identified
this peptide as an optimal synthetic epitope (41).
TAP Affinities of Epitopes and Extended Variants. TAP af-
finity, the second parameter likely to affect efficiency of pre-
sentation, was evaluated with the two available techniques,
Figure 1. TAP binding affinity of HBV peptides binding to HLA-A2.
Peptide sequences and HBV proteins of origin are indicated below the
graph. Peptides marked with an asterisk are frequently recognized by
CTLs from patients with acute HBV infections (37). Peptide affinities in
this and all other panels are expressed as normalized IC50, i.e., IC50 of
competitor peptide divided by IC50 of unlabeled reporter peptide mea-
sured in the same assay. Columns with broken tops in this and other fig-
ures indicate unmeasurable competition efficiency, i.e., in this case IC50
values above 3,000.
Figure 2. HLA-A2–binding affinities of selected epitopes and precur-
sors. HLA-A2–binding affinities of epitopes and Nt- and/or Ct-extended
variants were measured in competition binding assays using reporter pep-
tide F-10-V; mean normalized IC50 values from three independent exper-
iments are shown. The two sequences to the right correspond to reporter
peptides S-9-L and L-9-V used in transport experiments shown in Fig. 4.1232 Selection of ER-processed Epitope Precursors by Human TAP
TAP binding and transport assays. Transport assays (Fig. 3 A)
measure accumulation of glycosylated peptide in the ER of
streptolysin O–permeabilized cells (31), which is TAP and
ATP dependent but also affected by other processes, such as
peptide degradation and active depletion from the ER. TAP
binding assays (Fig. 3 B) evaluate at low temperature the
initial step of peptide binding to the transporter in which
substrate is selected (9, 40). Largely equivalent results were
obtained with the two assays. For both epitopes, Nt exten-
sion by one or two residues increased TAP affinity to low
to intermediate levels (IC50 of 57–372 in binding assay). Ct
extension of the core epitope but not of pol 575-83 increased
affinity, and combination of both extensions resulted in
high TAP affinity of the core 17-28 variant (IC50 of 1.1).
Ct-extended variants (pol 573-87 and core 18-28 peptides)
competed less efficiently in transport than in binding assays;
this may be due to peptide modification by cytosolic car-
boxypeptidases or peptide degradation in transport assays.
Thus, for both epitopes, Nt-extended variants and, for the
core epitope, also a Ct-extended variant with higher TAP
affinity could be identified.
A Pathway with Low Efficiency Provides Access to the ER to
Epitopes and Extended Variants in TAP-deficient Cells. Some
peptides can be presented by HCI molecules in a TAP- and
signal sequence–independent fashion (42). Moreover, some
epitopes are presented with high efficiency in TAP-deficient
T2 cells when expressed as minigenes (43). To test whether
the selected epitopes and their variants could enter the ER in
a TAP-independent manner, we adopted a transport assay in
which labeled reporter peptides bind to newly synthesized
HCI molecules and can be recovered by immunoprecipita-
tion of the latter (32). To monitor TAP-independent pep-
tide access to the ER, we used a human T cell lymphotro-
phic virus type 1–derived reporter peptide (L-9-V) with high
binding affinity for HLA-A2 (Fig. 2) that has been shown to
be presented efficiently in TAP-deficient cells when expressed
as a minigene (43); assembly of L-9-V with HLA-A2 was
measured in permeabilized T2 cells (Fig. 4 A).
The amount of L-9-V entering the ER and assembling
with HLA-A2 decreased sevenfold in the absence of func-
tional TAP complexes (not shown); addition of ATP did
not increase recovery of HLA-A2–bound peptide, suggest-
ing that TAP- and signal peptide–independent ER access is
a relatively inefficient process that does not require ATP.
As shown in Fig. 4 A, the two minimal epitopes and most
single-extended precursor peptides competed for assembly
of L-9-V with HLA-A2 in T2 cells and were therefore able
Figure 3. TAP affinities measured in transport and binding assays. (A)
Inhibition by epitopes and their variants of accumulation of glycosylated
reporter peptide R-10-T in streptolysin O–permeabilized cells was mea-
sured; results equivalent to those shown were obtained with a second re-
porter peptide, S-11-R. (B) Mean normalized IC50 values from three
TAP binding experiments. Broken tops marked with an asterisk in Figs. 3
and 4 indicate values obtained by extrapolation.
Figure 4. TAP-independent or -dependent assembly of peptides with
HLA-A2 molecules in permeabilized cells. (A) Permeabilized HLA-A21
TAP-deficient T2 cells were incubated with labeled reporter peptide
L-9-V; HLA-A2–bound reporter peptide was then quantified by immu-
noprecipitation with mAb BB7.2. (B) Permeabilized TAP-proficient A21
JY cells were incubated with reporter peptide S-9-L followed by immu-
noprecipitation. Unspecific reporter peptide assembly with HLA-A2 was
z10%.1233 Lauvau et al.
to enter the ER in TAP-deficient cells; differences in IC50
values were relatively small. Double-extended precursors
did not compete at all. High amounts of three unrelated
9-mer peptides binding to HLA-B40 and the HLA-B27–
binding peptide S-9-R, a peptide reported to enter the ER
when expressed as a minigene in TAP-deficient cells (43),
also did not compete (not shown). This suggests that TAP-
independent ER entry does not involve interaction with a
saturable substrate binding site of a transporter or channel.
As reporter and competitor peptides competed for TAP-
independent ER access as well as binding to HLA-A2, it is
possible that the observed differences were due to distinct
HLA-A2 binding affinities. However, measured A2 affini-
ties (Fig. 2) did not fully explain competition efficiencies in
TAP-independent transport assays, so that distinct efficien-
cies of ER access are likely to contribute to experimental
results. Thus, TAP-independent peptide entry into the ER
of permeabilized cells displayed relatively low efficiency as
well as selectivity and appeared not to correspond to an ac-
tive process, as indicated by lack of ATP requirement and
absence of sensitivity to competition.
Dominant Role of TAP Affinity for Efficiency of Assembly of
Cytosolic Peptides with HLA-A2 In Vitro. We finally tested
peptides in an in vitro assay that is likely to reflect the com-
bined effect of the parameters evaluated above. In this as-
say, peptides competed for TAP-dependent and -indepen-
dent ER entry and binding to HLA-A2 molecules of reporter
peptide S-9-L with high TAP affinity (IC50 5 2.3; refer-
ence 8) and an intermediate HLA-A2 binding affinity (IC50 5
12.9; Fig. 2). The two epitopes showed a distinct pattern of
relative competition efficiencies of minimal and extended
epitope forms (Fig. 4 B). Isolated Nt extension by one or
two residues (including a single methionine) significantly
increased efficiency of competition; however, Ct or double
extension slightly increased competition efficiency of the
pol peptide, whereas it dramatically decreased that of the
core peptide.
In view of the evaluation of isolated parameters described
above, the distinct efficiencies of accumulation can be inter-
preted as follows. Increased efficiency of single Nt-extended
variants could only be due to higher TAP affinities, as TAP-
independent ER access of these peptides was unchanged and
HLA-A2 affinities were equal (pol 573-83) or significantly
decreased (methionine–pol 575-83, both core variants). Im-
portantly, the low HLA-A2 affinities of three Nt-extended
precursors did not appear to affect efficiency of competi-
tion; this suggests that either the negative effect on HLA-A2
affinity of Nt extension observed in equilibrium binding
assays is not present during initial peptide assembly with
HLA-A2 measured in the assay described here or that Nt
extensions were removed by an ER-resident trimming ac-
tivity during the assay, thereby increasing peptide affinity
for HLA-A2.
Although Ct- or double-extended variants of HBV core
18-27 were very similar to Nt-extended variants with re-
spect to reduced HLA-A2 affinities and increased TAP af-
finities, they competed for assembly with HLA-A2 in per-
meabilized cells with greatly reduced efficiency and thus
differed strikingly from Nt-extended variants. In view of
previous reports demonstrating the absence of a Ct trimming
activity in the ER (10, 19), this discrepancy suggests that Nt
but not Ct peptide trimming in the ER occurs during trans-
port experiments as described here and that Ct-extended
variants do not compete efficiently in these experiments
because of their low affinity for HLA-A2. Alternatively,
only the negative effect of Ct extensions on HLA-A2 affin-
ity, but not that of Nt extensions observed in equilibrium
binding assays, may act during initial peptide assembly with
HLA-A2.
Taken together, HCI and TAP affinities both contrib-
uted to selection of epitope forms that can enter the ER
and assemble with HCI molecules in our experimental sys-
tem in vitro. Extended epitope forms with increased TAP
affinities entered into the ER with greatly increased effi-
ciency; subsequent efficient assembly with HLA-A2 was
restricted to epitope forms with high HLA-A2 affinities and
epitope precursors with lower HLA-A2 affinities due to Nt
but not Ct extensions. However, a TAP-independent path-
way provided access to the ER even to epitope forms with
very low TAP affinities, albeit with reduced efficiency. As
very small quantities of antigenic peptides can be sufficient
for T cell recognition, and because some factors influencing
peptide presentation by intact cells may not be readily mea-
surable by the applied techniques in vitro, we decided to
examine the importance of the described in vitro findings
for presentation of the various epitope forms to specific
CTL lines.
TAP Affinity Determines Efficiency of Presentation of Peptides
Expressed as Minigenes. We expressed minimal epitopes,
Nt-extended precursors, and minimal epitopes preceded by
the E3/19K signal sequence as minigenes in recombinant
vaccinia viruses in order to obtain high peptide levels in the
cytosol or ER, respectively. In parallel, HLA-A2–restricted
specific CTL lines were generated using three different
approaches: in vitro priming and expansion of PBMCs from
healthy donors by successive restimulation with autologous
irradiated PBMCs pulsed with synthetic minimal epitopes
(35), short-term expansion of secondary CTL lines by pep-
tide restimulation of PBMCs from patients with acute HBV
infections (37), DNA immunization with plasmids encod-
ing full-length HBV proteins of two transgenic mouse lines
expressing HLA-A2/Kb heavy chain and human b2m en-
coded by two transgenes (38), or a single chain construct
(30). All used CTL lines met the following criteria: (a) spe-
cific recognition of target cells pulsed with synthetic minimal
and Nt-extended epitope variants and (b) recognition of nat-
urally processed epitope presented by HLA-A21 target cells.
Most CTL lines were tested for relative efficiencies of
recognition of short and extended epitope forms. All tested
lines specific for pol 575-83 and core 18-27 recognized
both short and Nt-extended epitope forms; however, rec-
ognition of epitope precursors generally required 10–50-
fold higher peptide concentrations than that of minimal
epitopes (not shown). In the case of the core epitope, CTL
recognition of Nt-extended longer peptides is also in ac-
cordance with a previous study (41). CTL recognition of1234 Selection of ER-processed Epitope Precursors by Human TAP
synthetic precursor peptides was not due to contamination
by truncated peptides (44); high resolution HPLC analysis
of synthetic precursor peptides combined with mass spec-
trometric analysis demonstrated absence of contaminating
minimal epitopes (not shown). CTL lines generated by im-
munization in vivo (patients/transgenic mice) generally lost
recognition of short synthetic peptides at 10212 M, whereas
lines derived by in vitro immunization lost recognition at
10210 M. To ascertain that experiments with vaccinia viruses
reflected intracellular assembly of peptides with HLA-A2
molecules and not binding to cell surface HLA-A2 mole-
cules of peptides released from lysed infected cells, we also
performed control experiments in which export of newly
ER-assembled HLA-A2 molecules to the cell surface was in-
hibited by BFA (39). As expected, this treatment completely
inhibited presentation of minigene-expressed epitopes but
did not affect presentation of synthetic peptides (not shown).
As shown in Fig. 5, CTL lines recognizing epitope pol
575-83 killed target cells much more efficiently when these
expressed the Nt-extended precursor 573-85 than cells ex-
pressing the minimal peptide 575-83. Lysis of cells express-
ing the precursor was similar to lysis of cells pulsed with
short synthetic peptides or expressing full-length pol pro-
tein, whereas cells expressing the minimal epitope were
hardly recognized at all in an experiment with a CTL line
from a patient (Fig. 5 A). A similar although less dramatic
difference in recognition was obtained with two CTL lines
obtained by in vitro immunization (Fig. 5 B and data not
shown). In contrast, one of these lines recognized TAP-defi-
cient T2 cells expressing the two epitope forms with equal,
intermediate efficiency, demonstrating that more efficient
sensitization by expression of the precursor form was due to
TAP-mediated ER access of this epitope variant (Fig. 5 C).
An even more dramatic effect of Nt epitope extension
was observed for epitope core 18-27 and its precursor, 17-27
(Fig. 5 D). In this case, the HBV patient–derived line did not
kill cells expressing the minimal epitope but recognized pre-
cursor peptide–expressing cells and cells expressing the core
protein or the signal peptide–coupled epitope with equally
high efficiency. Equivalent results were obtained with a CTL
line derived from another patient (Fig. 5 E) and a line gen-
erated by in vitro immunization (not shown).
In conclusion, investigation of presentation of minigene-
expressed epitopes and Nt precursors confirmed results ob-
tained in vitro and underlined the dominant role of TAP in
selecting variants of two HLA-A2–presented epitopes for
presentation, as well as the low efficiency of TAP-indepen-
dent ER access. Concordant results of in vitro and ex vivo
experiments suggested that all major parameters controlling
presentation of the two epitopes had been analyzed in vitro.
However, it was not clear whether the TAP-selected precur-
sors were presented in an unmodified or shortened form.
A TAP-translocated Precursor Peptide with Low HLA-A2
Binding Affinity Undergoes Nt Processing in the ER. To find
out  whether precursor peptides could be processed in the ER,
we analyzed HLA-A2–presented peptides from minigene-
expressing cells. HLA-A2 molecules were purified from JY
cells expressing minimal or Nt-extended forms of epitopes
pol 575-83 and core 18-27, and peptides associated with
purified HLA-A2 molecules were analyzed according to
published methods (21). Acid-eluted peptides were fraction-
ated under HPLC conditions that allowed maximal separa-
tion of synthetic peptides corresponding to minimal epitopes
and the two Nt-extended precursors for each of the epitopes;
peptides extended by an Nt methionine were included in
calibration experiments to allow detection of vaccinia-
expressed minimal epitopes having undergone incomplete
processing by cytosolic methionine aminopeptidase. Each
fraction was tested for its capacity to sensitize HLA-A21 cells
for lysis by specific CTL lines. Unspecific lysis was determined
as the mean lysis obtained by sensitization with fractions
from control IVD12-coated beads and was always ,15%.
In the case of epitope pol 575-83, only the epitope forms
encoded by the minigenes could be detected in fractions
eluted from HLA-A2 (Fig. 6 A). Specifically, elutions from
cells expressing precursor 573-85 did not contain sensitiz-
ing activity with the retention time corresponding to the
minimal epitope; in addition, elutions from cells expressing
Figure 5. Efficiency of presentation of minigene-expressed minimal
epitopes and Nt-extended precursors to specific CTL lines. Target cells
were sensitized by synthetic peptides, by vaccinia viruses corresponding
to different forms of epitopes indicated in the panels, or by control vi-
ruses, and lysis by CTL lines specific for the indicated epitopes was mea-
sured. Symbols indicate target cell sensitization by the following reagents:
n, synthetic peptide corresponding to minimal epitope; e, irrelevant
vaccinia virus; r, vaccinia virus expressing the appropriate full-length
HBV protein; u, vaccinia-expressed short epitope preceded by the E3/
19K signal sequence; d, vaccinia-expressed short epitope; s, vaccinia-
expressed, Nt-extended precursor peptide. (A) Lysis of JY target cells by a
patient-derived CTL line. (B) Lysis of Jesthom cells by a line derived by
in vitro immunization. (C) Lysis of T2 cells by the same line as in B. (D
and E) Lysis of JY cells by two CTL lines derived from different acutely
HBV-infected patients.1235 Lauvau et al.
the short epitope form did not contain sensitizing material
in the fraction corresponding to the methionine-extended
epitope (not shown). The same result was obtained with a
second CTL line obtained from an HLA-A2– transgenic
HHD mouse (not shown). Thus, there was no evidence for
cleavage of the pol 573-83 precursor peptide in the ER.
Significant amounts of the short epitope were detected
in HLA-A2–eluted material from cells expressing the mini-
mal epitope pol 575-83 (Fig. 6 A). We have so far not been
able to quantify the peptide contained in these fractions, al-
though indirect evidence allows us to conclude that elutions
from precursor peptide–expressing cells are likely to contain
significantly more sensitizing peptide than those from cells
expressing the short epitope. Due to its generation by in
vitro immunization with pol 575-83, the CTL used for anal-
ysis of fractions recognized peptide 575-83 with 40–50-fold
higher efficiency than peptide 573-83 (Fig. 6 B). As CTL
recognition of sensitizing fractions from cells expressing pol
575-83 and 573-83 was equally efficient, it is likely that frac-
tions from cells expressing and presenting peptide 573-83
contain substantially more peptide than those from cells ex-
pressing peptide 575-83. Detection of a low amount of pep-
tide 575-83 in elutions from pol 575-83/vaccinia–infected
cells is consistent with low-level killing of such cells by the
same CTL line (Fig. 5 B).
Results for elutions from cells expressing the core
epitope or its precursor were strikingly different from those
for the pol epitope (Fig. 6, C and D). Both cells synthesiz-
ing the short and the extended epitope form exclusively
presented the minimal epitope; in addition, HLA-A2 mol-
ecules from cells expressing the precursor peptide contained
substantially larger quantities of this peptide than A2 mole-
cules from cells expressing the short form (Fig. 6 C). The
epitope variant extended by an Nt methionine could not
be detected in cells expressing core 18-27 preceded by a
methionine initiation codon (not shown). Results shown
in Fig. 6 C were obtained with a patient-derived CTL line;
equivalent results were obtained with three other CTL lines
raised in conventional or HHD-transgenic mice (not shown).
Thus, in cells expressing precursor peptide HBV core 17-27,
apparently complete Nt processing in the ER was observed.
When peptides eluted from cells expressing complete HBV
core protein were analyzed, sensitizing activity also comi-
grated exclusively with the fraction corresponding to pep-
tide core 18-27 (Fig. 6, E and F), demonstrating that this pep-
tide is also the dominant epitope form generated from the
source protein.
Detection of peptide HBV core 18-27 but not 17-27
might be due to more efficient CTL recognition of the
shorter peptide, a standard feature of all CTL lines described
in this paper, including the two lines generated from
HHD-transgenic mice used for analysis of eluted material
(Fig. 6, C and E). To address this issue, dilutions of syn-
thetic peptides and of sensitizing fractions of eluted material
were analyzed for CTL recognition. Both CTL lines rec-
ognized peptide 18-27 with 10-fold higher efficiency than
17-27 (not shown). CTL lines recognized a 500-fold dilu-
tion of the fraction from cells expressing the core 17-27
minigene (Fig. 6 D) and a 40-fold dilution of the fraction
from cells expressing the HBV core protein (Fig. 6 F). Con-
sequently, cells expressing minigene core 17-27 contained at
least 50 times more peptide core 18-27 than 17-27, whereas
cells expressing HBV core protein contained at least four
times more of the short peptide. Titration experiments with
synthetic peptide standards and elution fractions also allowed
us to calculate the number of HLA-A2–extracted HBV core
Figure 6. Peptides presented by cells expressing minimal or Nt-
extended epitopes. HLA-A2 molecules were purified from JY cells express-
ing vaccinia virus–encoded minigenes, and peptides eluted by acid treat-
ment of A2 molecules were fractionated and tested for recognition by
specific CTL lines. Elution times of synthetic peptides analyzed under
identical HPLC conditions are indicated in A, C, and E by solid arrows
(minimal epitope forms) and open arrows (Nt-extended precursors), re-
spectively. In A–D, filled symbols represent elutions from cells expressing
minimal epitopes (or incubation with the corresponding synthetic peptide
in B), and open symbols correspond to Nt-extended precursors. Target
cells were T2 cells in A–C and RMA-S HHD transfectants in D–F. CTL
lines were derived by in vitro immunization (A and B, same line used as
in Fig. 5, B and C), from an HBV patient (C), or from two different
HHD-transgenic mice (one line used in D, the other used in E and F).
(A) Sensitization by fractionated peptides from cells expressing HBV pol
575-83 or its Nt-extended precursor 573-83. (B) Efficiency of CTL rec-
ognition of synthetic peptides HBV pol 575-83 and pol 573-83. (C) Sen-
sitization by A2-eluted peptide fractions from cells expressing HBV core
18-27 or its precursor, core 17-27. (D) Sensitization by dilutions of frac-
tion 3 eluted from HLA-A2 molecules of cells expressing HBV core 18-27
or core 17-27. (E) Sensitization by fractionated peptides from cells express-
ing vaccinia-encoded HBV core protein. (F) Sensitization by dilutions of
fraction 7 eluted from HLA-A2 molecules of cells expressing vaccinia-
encoded HBV core protein.1236 Selection of ER-processed Epitope Precursors by Human TAP
18-27 molecules per cell. This number was 3,610 for cells
expressing the core 17-27 minigene, 438 for the core 18-27
minigene, and 20 for core protein.
Discussion
Two principal novel findings emerge from this study: (a)
the selectivity of human TAP can have a substantial biolog-
ical impact on peptide entry into the ER and (b) similar to
signal peptide or Jaw 1–coupled epitopes, TAP-transported
peptides can be modified by a highly efficient aminopepti-
dase activity in the ER. To our knowledge, this is the first
conclusive demonstration that the human peptide trans-
porter can participate in peptide selection for presentation
by HCI molecules. Thus, previously established rules gov-
erning peptide affinity for human TAP (8, 14) are biologi-
cally relevant.
In a comparison of the data reported here with earlier
demonstrations of the biological impact of murine and rat
TAP-B transporters (10, 12), an important difference needs
to be emphasized. Significant biological effects of peptide
selection by restrictive rodent transporters have been dem-
onstrated in settings where TAP and MHC preferences for
Ct peptide residues were incompatible. Due to the absence
of Ct peptide processing in the ER (10), these incompati-
bilities cannot be compensated for after TAP transport and
impair the efficiency of class I antigen processing so severely
that incompatible TAP/MHC combinations have not sur-
vived in rat evolution (11). This study addresses the biolog-
ical impact of TAP selection in a setting where Ct prefer-
ences of TAP and MHC class I molecules are adapted overall
(as is the case in humans), and some peptides display low TAP
affinities due to Nt as well as Ct sequence elements. In this
setting, we find a dramatic effect of TAP affinity similar to
previous studies of rodent transporters. However, in the
absence of an overwhelming conflict between Ct prefer-
ences of human TAP and MHC class I molecules, transport
of Nt-extended peptides followed (when required) by Nt
processing in the ER allows highly efficient presentation of
epitopes with very low TAP affinities. This suggests that, in
humans, high permissiveness of the class I processing sys-
tem downstream from proteolytic peptide generation is not
due to absence of selectivity of TAP transporters but to a
combination of TAP transport of epitope variants with Nt
peptide processing in the ER.
Our analysis of a panel of HBV- and HCV-derived pep-
tides (Fig. 1), with many of them representing in vivo im-
munodominant epitopes (37), suggests that precursor peptide
selection by human TAP is a relatively common occur-
rence for HLA-A2–presented peptides. The frequent require-
ment for ER processing of ligand precursors for this molecule
is likely to reflect the poor compatibility of HLA-A2 and
TAP preferences. In a recent analysis of the compatibility
of human TAP preferences with those of nine HCI mole-
cules, HLA-A2 ligands showed the poorest and HLA-B27
ligands the best adaptation to TAP selectivity (14). How-
ever, close analysis of the TAP affinities of in vivo antigenic
HBV peptides (Fig. 1) suggests that antigen processing
may favor peptides that do not require ER processing.
Whereas only 2/12 peptides with very low TAP affinities
(IC50 .1,000) are known to be antigenic in vivo, this is the
case for 3/6 peptides with intermediate to high TAP affini-
ties (IC50 ,100). This may indicate limited efficiency of the
ER aminopeptidase or a requirement of specific flanking
sequences for its activity.
As it is not possible to quantitate antigenic peptides in
the cytosol, we do not know the expression levels of the
minigene-expressed epitope forms. In a study by Anton et al.,
vaccinia virus–expressed, MHC class I–bound epitopes were
detected at at least 50,000 copies per cell (45). We cannot
entirely rule out that 9- or 10-mer epitope forms are pro-
duced at lower levels than 11-mer precursors, although
there is no experimental evidence supporting this hypothe-
sis. However, in complete accordance with results obtained
with minigene-infected cells, synthetic precursor peptides
assembled much more efficiently with HLA-A2 in perme-
abilized cells than shorter minimal epitopes. This suggests
strongly that the dramatic difference between the efficiencies
of sensitizations by minigene-expressed precursor and min-
imal peptides was due to more efficient TAP transport of
precursors and not to lower expression of shorter epitope
forms. We therefore conclude that, in the studied cases, high
cytosolic concentrations of minimal epitopes could not
compensate completely for low TAP affinities. It is likely
that ER entry of minimal or extended epitope forms pro-
duced at physiological, i.e., lower concentrations generally
requires higher TAP affinities than in the case of the two
HBV-derived epitopes and their variants.
For the core 18-27 epitope, we were able to determine
the nature and number of peptide molecules eluted from
HLA-A2 molecules of cells expressing different epitope
forms. This analysis revealed that peptide core 18-27 is the
dominant HLA-A2–bound epitope form in cells expressing
its precursor 17-27 and also in cells expressing the complete
HBV core protein. Thus, in the case of this immunodomi-
nant HBV epitope, the naturally processed epitope form is
excluded from the ER by low TAP affinity, demonstrating
that TAP-imposed ER import of epitope precursors for lu-
minal processing plays a role in natural antigen processing.
Whatever the nature of precursor peptides of core 18-27
generated by cytosolic degradation of the HBV core pro-
tein, such precursor peptides must undergo ER processing
similar to peptide core 17-27. Quantitative analysis of
eluted fractions also demonstrated almost 10-fold higher
amounts of core 18-27 peptide in elutions from cells ex-
pressing the precursor peptide, as compared with cells ex-
pressing the minimal peptide. The relatively low number of
20 peptide molecules per cell expressing HBV core is com-
patible with immunodominance of this epitope in HBV-
infected patients. As few as three peptide molecules per cell
can give rise to efficient CTL lysis (46). Anton et al. found
a low number of 30 molecules per cell for an immu-
nodominant viral epitope generated from the vaccinia-
encoded source protein; as in this study, peptide copy num-
ber was dramatically increased upon expression of the epitope
as minigene (45). Results of Pamer et al. also suggest that1237 Lauvau et al.
immunodominance does not require high peptide copy
numbers (47).
The relatively high peptide copy number in cells express-
ing the core 18-27 minigene clearly conflicts with CTL rec-
ognition of vaccinia-infected targets (Fig. 5); three indepen-
dent CTL lines from different individuals recognized targets
expressing whole core protein with high efficiency but targets
expressing core 18-27 barely or not at all. We propose that
the number of 438 peptide molecules per cell may be due to
binding of cytosolic peptides to HLA-A2 molecules during
overnight incubation of cell lysates for A2 immunoprecipita-
tion. Although current consensus holds that antigenic pep-
tides can only be recovered from cells expressing a restricting
MHC class I molecule (1, 48), to our knowledge there is no
experimental evidence to rule out that peptide–MHC com-
plexes can be formed after cell lysis. Based on reports that as
many as 50,000 peptides per cell can be presented by MHC
class I molecules in cells expressing vaccinia-encoded mini-
genes (45), it can conservatively be assumed that at least
100,000 peptide molecules per cell are synthesized in such
cells. Provided that these peptides are not (or not entirely) de-
graded and at least partly set free in detergent lysates, this
would correspond to a maximum peptide concentration of
8 nM during immunoprecipitation of HLA-A2 under the
conditions employed in this study. This concentration is not
very far from the KD of 40 nM of peptide core 18-27 (Lau-
vau, G., and P.M. van Endert, unpublished data). Corrobora-
tion of the hypothesis of cytosolic peptide association with
HLA-A2 after cell lysis will require lysate mixing experiments
followed by peptide elution and analysis.
Based on the identification of epitopes that cannot enter
the ER in their minimal form, we have been able to study
ER processing of TAP-translocated peptides. We find that
precursor peptide pol 573-83 is presented without modifica-
tion, presumably due to its high-affinity binding to HLA-A2;
efficient binding of up to 12-mer peptides to HLA-A2 has
been reported previously (49). Apparently complete process-
ing of precursor peptide core 17-27 with low HLA-A2 affin-
ity suggests that ER processing of precursor peptides may be
controlled by HCI binding affinity but unaffected by peptide
length; both precursor peptides are 11-mers.
Although the reported data establish clearly that TAP-
transported precursor peptides can be processed in the ER,
it remains unclear whether the involved mechanism is
identical to that implicated in release of epitopes coupled to
signal sequences (19). We have so far not been able to in-
vestigate in our system the effect of protease inhibitors that
have been reported to inhibit assembly of signal sequence–
derived peptides with HLA-A2 (50). Although the obser-
vation of an unusual length of signal sequence–derived
peptides in TAP-deficient cells (27) may indicate distinct
peptide maturation mechanisms in the two cases, involve-
ment of an identical or similar mechanism is suggested by
the apparent lack of Ct processing in both systems (19, 21).
It is also possible that several proteolytic events are involved
in epitope generation from signal sequences, only one of
which also acts on peptides delivered by TAP.
We can now only speculate on the mechanism of Nt
peptide processing. Our analysis of HLA-A2–eluted pep-
tides may provide clues in this regard. Nt peptide processing
may be carried out by a fluid phase or directly HCI-associ-
ated aminopeptidase. Although both scenarios could ex-
plain processing of precursor core 17-27, the complete ab-
sence of processing of precursor pol 573-83, as detected in
elutions, is difficult to reconcile with random fluid phase
processing. We therefore favor the alternative scenario, in
which unstable HCI association of Nt-extended epitope
precursors would be detected by a sensor mechanism inte-
grated into or coupled to the putative peptidase. Sensor and
processing mechanisms may preferentially associate with
HCI molecules interacting with TAP–tapasin complexes.
This hypothesis could also account for the frequent finding
of long peptides bound to HLA-A2 in TAP-deficient cells
and to HLA-B27 in normal cells; a recent report suggests
that HLA-B27 may frequently assemble with peptides in a
tapasin-independent fashion (26). Several proteins involved
in peptide loading on HCI molecules are candidates for the
putative role of aminopeptidase. These include HCI mole-
cules themselves (51), the ER-resident chaperone gp96
(52), and the putative chaperone tapasin (4).
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